The current Italian turnover
for ethical products 75% of which is sold by the public channel
and 25% by the hospital channel, places Italfarmaco among
the top 30companies on the Italian pharmaceutical market,
and 5th among groups with Italian capital.
The traditional core business
is represented by the cardiovascular and immuno-oncological
areas, which account for 60% and 40% of domestic turnover
respectively.
Therapeutic
area
%
turnover
Cardiovascolar
44
Immuno-oncological
37
Dermatological/Gynaecological
5
Neurological
14
In these
segments, the Group holds significant competitive positions,
as in the field of heparins.
The Group's marketing activities, designed to promote the products
in its range by providing the medical profession with scientific
information based on the maximum accuracy and scientific rigour,
are performed by allocating suitable resources to in-house structures
(Product Management, Sales Promotion and Training) and external
organization (pharmaceutical sales representatives).
External
resources
Workforce
Lines
Cardiovascolar
Dermatological Gynaecological
Immuno
oncological
Area
Manager
14
3
3
Clinic/hospital
reps
45
-
40
Pharmaceutical
sales reps
220
35
-
The network of pharmaceutical sales representatives is divided
in two lines, cardiovascular and immuno-oncological (with 204, 38
and 43 reps respectively), and guarantees widespread coverage
of the country, as demonstrated by visits to more than 100,000
doctors, 65% of whom are specialists.
In
addition to the scientific information activities conducted
through the Group's structures, Italfarmaco is firmly committed
to offering doctors the opportunity to obtain detailed, up-to-date
scientific information on subjects closely related to the therapeutic
fields in which they are mainly involved. This requires the
organisation of congresses, scientific conventions, training
courses and hospital meetings, with which national and international
opinion leaders are asked to collaborate.
The current Italian turnover
for ethical products 75% of which is sold by the public channel
and 25% by the hospital channel, places Italfarmaco among
the top 30companies on the Italian pharmaceutical market,
and 5th among groups with Italian capital.
In
addition to the scientific information activities conducted
through the Group's structures, Italfarmaco is firmly committed
to offering doctors the opportunity to obtain detailed, up-to-date
scientific information on subjects closely related to the therapeutic
fields in which they are mainly involved. This requires the
organisation of congresses, scientific conventions, training
courses and hospital meetings, with which national and international
opinion leaders are asked to collaborate. 
